Table 3: Cost, doses and population at risk for universal palivizumab prophylaxis for healthy infants with scenarios A* and B† during the 2009 RSV season
Age; weight, kgMonth; monthly cost per dose per eligible healthy term infant, $December 2008January 2009February 2009March 2009April 2009May 2009 Birth; 3.5880880880880880880 1 mo; 4.3106910691069106910691069 2 mo; 5.05124712471247124712471247 3 mo; 5.75141314131413141314131413 4 mo; 6.45157915791579157915791579 5 mo; 7.0170917091709170917091709 6 mo; 7.55-18401840184018401840 7 mo; 8.05--1958195819581958 8 mo; 8.45---205320532053 9 mo; 8.85----21482148 10 mo; 9.25-----2243Sum Sum scenario A7897973711 69513 74815 89618 13977 112 Sum scenario B78977897789778977897789747 382 Note: RSV = respiratory syncytial virus. *Scenario A: Eligible infants are those who would be less than 6 months of age by Jan. 1, 2009 or born before May 31, 2009. Prophylaxis is stopped by May 31, 2009. Annual cost per region =$6423.82 × number of births/year. Monthly doses = number of doses per month x 1/12 × births/year. Annual doses = 51 × 1/12 births/year = 4.25 × births/year. Population at risk = 51/72 × births/year.

†Scenario B: Eligible infants are those who would be less than 6 months of age by Jan. 1, 2009 or born before May 31, 2009. Prophylaxis is stopped by 6 months of age. Model assumes that an equivalent number of infants are born as surpass the age criteria. Annual cost per region = $7897/month × 6/12 births/year =$3947.29 × births. Monthly doses = number of doses per month × 1/12 birth/year = 6/12 × births. Annual doses = 6 × 6/12 births/year. Population at risk = 36/72 × births/year.